A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma

NCT01445587 · clinicaltrials.gov ↗
PHASE2
Phase
WITHDRAWN
Status
INDUSTRY
Sponsor class

Stopped Based on the clinical activity, not safety data, of the AKT inhibitor, GSK has decided at this time to suspend further development of GSK2110183 as monotherapy.

Conditions

Interventions

Sponsor

GlaxoSmithKline